Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA)

被引：1
|
作者：
Sajeev, G. [1 ]
Evans, R. [2 ]
Hawkins, N. [2 ,3 ]
Mahajan, A. [4 ]
Scott, D. [2 ]
Nam, J. [5 ]
Sutherland, S. [5 ]
Kokaliaris, C. [5 ,6 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Visible Analyt, Oxford, England
[3] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
[4] Bridge Med Consulting Ltd, London, England
[5] F Hoffmann La Roche Ltd, Global Access, Basel, Switzerland
[6] Roche Prod Ltd, Welwyn Garden City, Herts, England
来源：
NEUROMUSCULAR DISORDERS | 2023年 / 33卷
关键词：
D O I：
10.1016/j.nmd.2023.07.385
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P08
引用
收藏
页码：S164 / S164
页数：1
相关论文
共 50 条
  • [31] RAINBOWFISH: Primary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA)
    Finkel, R.
    Farrar, M.
    Servais, L.
    Vlodavets, D.
    Zanoteli, E.
    Al-Muhaizea, M.
    Prufer, A.
    Nelson, L.
    Fischer, C.
    Gerber, M.
    Gorni, K.
    Kletzl, H.
    Palfreeman, L.
    Gaki, E.
    Fontoura, P.
    Bertini, E.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S88 - S88
  • [32] Performance fatigability in adults with spinal muscular atrophy treated long-term with nusinersen
    Stolte, Benjamin
    Neuhoff, Svenja
    Lipka, Jaqueline
    Schlag, Melina
    von Velsen, Otgonzul
    Kruse, Teresa
    Deuschl, Cornelius
    Kleinschnitz, Christoph
    Hagenacker, Tim
    MUSCLE & NERVE, 2024, 70 (06) : 1223 - 1229
  • [33] How children and caregivers viewed the change from nusinersen to risdiplam for treating spinal muscular atrophy
    Agosto, Caterina
    Benedetti, Francesca
    Salamon, Eleonora
    Mercante, Anna
    Papa, Simonetta
    Giacomelli, Luca
    Santini, Anna
    Benini, Franca
    ACTA PAEDIATRICA, 2023, 112 (02) : 311 - 312
  • [34] Long-term benefits of nusinersen in later-onset spinal muscular atrophy
    Ian Fyfe
    Nature Reviews Neurology, 2019, 15 (7) : 368 - 369
  • [35] Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2
    Iwayama, Hideyuki
    Kawahara, Kohei
    Takagi, Mizuki
    Numoto, Shingo
    Azuma, Yoshiteru
    Kurahashi, Hirokazu
    Yasue, Yumiko
    Kawajiri, Hiroyuki
    Yanase, Atsushi
    Ito, Teruyoshi
    Kimura, Shinya
    Kumagai, Toshiyuki
    Okumura, Akihisa
    BRAIN & DEVELOPMENT, 2023, 45 (02): : 110 - 116
  • [36] Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)
    Oskoui, Maryam
    Day, John W.
    Deconinck, Nicolas
    Mazzone, Elena S.
    Nascimento, Andres
    Saito, Kayoko
    Vuillerot, Carole
    Baranello, Giovanni
    Goemans, Nathalie
    Kirschner, Janbernd
    Kostera-Pruszczyk, Anna
    Servais, Laurent
    Papp, Gergely
    Gorni, Ksenija
    Kletzl, Heidemarie
    Martin, Carmen
    McIver, Tammy
    Scalco, Renata S.
    Staunton, Hannah
    Yeung, Wai Yin
    Fontoura, Paulo
    Mercuri, Eugenio
    SUNFISH Working Grp
    JOURNAL OF NEUROLOGY, 2023, 270 (05) : 2531 - 2546
  • [37] Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)
    Maryam Oskoui
    John W. Day
    Nicolas Deconinck
    Elena S. Mazzone
    Andres Nascimento
    Kayoko Saito
    Carole Vuillerot
    Giovanni Baranello
    Nathalie Goemans
    Janbernd Kirschner
    Anna Kostera-Pruszczyk
    Laurent Servais
    Gergely Papp
    Ksenija Gorni
    Heidemarie Kletzl
    Carmen Martin
    Tammy McIver
    Renata S. Scalco
    Hannah Staunton
    Wai Yin Yeung
    Paulo Fontoura
    Eugenio Mercuri
    Journal of Neurology, 2023, 270 : 2531 - 2546
  • [38] MATCHING-ADJUSTED INDIRECT COMPARISON OF RISDIPLAM VERSUS NUSINERSEN IN TYPE 1 SPINAL MUSCULAR ATROPHY: 2-YEAR UPDATE
    Marti-Gil, Y.
    Ribero, Aponte, V
    Gorni, K.
    Daigl, M.
    Evans, R.
    Scott, D. A.
    Mahajan, A.
    Hawkins, N.
    VALUE IN HEALTH, 2022, 25 (12) : S44 - S44
  • [39] FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam in Type 1 spinal muscular atrophy
    Deconinck, N.
    Baranello, G.
    Boespflug-Tanguy, O.
    Day, J.
    Klein, A.
    Masson, R.
    Mazurkiewicz-Beldzinska, M.
    Mercuri, E.
    Rose, K.
    Servais, L.
    Vlodavets, D.
    Xiong, H.
    Zanoteli, E.
    El-Khairi, M.
    Gerber, M.
    Gorni, K.
    Kletzl, H.
    Dodman, A.
    Gaki, E.
    Darras, B.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 279 - 279
  • [40] Nusinersen in adults with type 3 spinal muscular atrophy: long-term outcomes on motor and respiratory function
    Serrao, Catarina
    Domingues, Sara
    de Campos, Catarina Falcao
    Moreira, Susana
    Conceicao, Isabel
    de Carvalho, Mamede
    Santos, Miguel Oliveira
    NEUROLOGICAL SCIENCES, 2024, 45 (06) : 2887 - 2891
12345